NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

NCT07127315

CompletedNA

Sponsor: Helwan University

Conditions: Gonadotropin Releasing Hormone Agonists, Ovarian Function, Premenopausal, Breast Cancer, Chemotherapy

Interventions: Gonadotropin-releasing hormone agonist, Chemotherapy

Countries: Egypt

The purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 45 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Premenopausal female patients 18-45 years.
* Female patients with pathologically confirmed breast cancer and receiving a chemotherapy regimen, either adjuvant or neoadjuvant, containing a gonadotoxic agent.
* Female patients with performance status (PS) ≤ 2.

Exclusion Criteria:

* All female Patients with metastatic cancer.
* Patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy, or patients received radiotherapy on the pelvis.
* Patient with end-organ failure.
* Patients with performance status \>2.
* Male with breast cancer.
* Post-menopausal females.

Locations (1)

Helwan, Helwan, Egypt